RxDoctor Payments Data

Eric Frykman, MD

Emergency Medicine · Riverside, CANPI 1205863909

Payments from drug & device makers

$1,379in general payments, 2019–2025

Across 55 payments — averaging $25.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$468
  • Abbott$163
  • Novo Nordisk$117
  • Xeris Pharmaceuticals, Inc.$109
  • Sanofi-aventis U.S. LLC$108
  • Tandem Diabetes Care, Inc.$106
  • plus $307 from 13 others

What the payments were for

  • Food & beverage$1,36799%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,379 in reported general payments places this provider in the 90th percentile of 6,006 emergency medicine providers in California.

See all emergency medicine providers in California

Medicare billing

Part B allowed, 2024
$74,079
Medicare patients
465
Services billed
1,039

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban33$43,185
MounjaroTirzepatide24$33,724
TrulicityDulaglutide16$25,644
OzempicSemaglutide14$15,183
OxycontinOxycodone Hcl13$10,851
SymbicortBudesonide/Formoterol Fumarate17$4,723
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen167$4,615
Lagevrio (Eua)Molnupiravir12$4,480
Atorvastatin Calcium262$3,562
Albuterol Sulfate HfaAlbuterol Sulfate105$3,037
Gabapentin94$2,868
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$2,834
Famotidine42$1,943
Acetaminophen-CodeineAcetaminophen With Codeine33$1,864
Omeprazole129$1,819

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$468$59,36840 claims
Novo NordiskOzempic$117$15,18314 claims
AbbVieSynthroid$15$92820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,006 emergency medicine providers in California.

Other emergency medicine in Riverside

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →